Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|January 27, 2022
Appropriate use criteria for PSMA-PET imaging will help guide clinicians
Author(s)Urology Times staff
Advertisement
In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, discusses what he hopes clinicians and patients take away from the recently released appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging in prostate cancer. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.
Advertisement
Related to this article
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to VIR-5500 for mCRPC
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
5